The U.S. Securities and Exchange Commission (SEC) charged Usama Malik with insider trading during his time as chief financial officer of Immunomedics, a biopharma he helped lead to a $21 billion exit via a Gilead Sciences acquisition last year.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,